All In Biotech

Drug Trial Radar · NCT06395753

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

May 23, 2024

Primary completion

Jun 24, 2026

Study completion Jul 22, 2026

Sponsor

Lead sponsor
Debiopharm International SAIndustry
Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.

Conditions

  • Prostate Cancer

Interventions

  • Debio 4228Drug

    Administered as IM injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of Debio 4228Time frame: Cohorts 1 and 2: Predose and at multiple time points post-dose up to Day 169; Cohort 3: Predose and at multiple time points post-dose up to Day 169
  2. Area Under the Concentration-time Curve of Debio 4228 Over 12 weeks (AUC84d)Time frame: Cohorts 1 and 2: Predose and at multiple time points post-dose up to Day 84; Cohort 3: Predose and at multiple time points post-dose up to Day 169
  3. Plasma Concentration of Debio 4228 at Week 12 (C84d)Time frame: Cohorts 1 and 2: Post-dose on Day 84; Cohort 3: Post-dose on Days 84 and 168
  4. Serum Concentration of TestosteroneTime frame: Cohorts 1 and 2: Predose and at multiple time points post-dose from Days 1 to 85; Cohort 3: Predose and at multiple time points post-dose from Days 1 to 169

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Urologic Surgeons of Arizona

    Mesa, Arizona

  • East Valley Urology Center of Arizona

    Queen Creek, Arizona

  • Bakersfield Institute of Advanced Urology

    Bakersfield, California

  • Grimaldi Urology

    Chula Vista, California

  • Valley Urology

    Fresno, California

  • Tower Urology,

    Los Angeles, California

  • Alarcon Urology Center

    Montebello, California

  • Urology Center of Southern California

    Murrieta, California

  • Biogenix Molecular

    Miami, Florida

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Oregon Urology Institut

    Springfield, Oregon

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology of Virginia

    Virginia Beach, Virginia

  • Summit Cancer Centers of North Spokane

    Spokane, Washington

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • CHU de Nantes - Hôtel Dieu

    Nantes, France

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic Barcelona

    Barcelona, Spain

  • Hospital Clinico San Carlos

    Madroñera, Spain

  • Instituto Valenciano de Oncologia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.